GSK Arexvy Protects From RSV Over Three Full Seasons
glaxosmithkline (GSK.US) claims that the protective effect of the RSV vaccine can last for three quarters.
GlaxoSmithKline (GSK.US) said on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.
UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Guggenheim Adjusts Pfizer Price Target to $36 From $35, Maintains Buy Rating
Market Chatter: Pfizer's Former Executives Pitch Starboard's Turnaround Plans to Board
2 Covered Call Ideas on Pfizer Stock